Novel vancomycin-peptide conjugate as potent antibacterial agent against vancomycin-resistant Staphylococcus aureus
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F62156489%3A43210%2F18%3A43914041" target="_blank" >RIV/62156489:43210/18:43914041 - isvavai.cz</a>
Alternative codes found
RIV/00216305:26620/18:PU129711
Result on the web
<a href="https://doi.org/10.2147/IDR.S160975" target="_blank" >https://doi.org/10.2147/IDR.S160975</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.2147/IDR.S160975" target="_blank" >10.2147/IDR.S160975</a>
Alternative languages
Result language
angličtina
Original language name
Novel vancomycin-peptide conjugate as potent antibacterial agent against vancomycin-resistant Staphylococcus aureus
Original language description
Background: Increase in vancomycin (Van)-resistant bacterial strains including vancomycinresistant Staphylococcus aureus (VRSA) and lack of new effective antibiotics have become a formidable health problem. Materials and methods: We designed a new conjugate composed of Van and a peptide Hecate (Hec; Van/Hec), and its potential antimicrobial activity was evaluated. Results: Results from disk diffusion test, time-kill assay, determination of minimum inhibitory concentration (MIC), microscopy, and comet assay showed strong antimicrobial effects of Van/Hec against wild-type, methicillin-resistant Staphylococcus aureus (MRSA) and VRSA. Microscopy revealed that the exposure to Van/Hec results in disruption of bacterial cell integrity in all tested strains, which was not observed in case of Van or Hec alone. Conclusion: Overall, we showed that the preparation of conjugates from antibiotics and biologically active peptides could help us to overcome the limitation of the use of antibiotic in the treatment of infections caused by multidrug-resistant bacteria.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30303 - Infectious Diseases
Result continuities
Project
<a href="/en/project/LQ1601" target="_blank" >LQ1601: CEITEC 2020</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>S - Specificky vyzkum na vysokych skolach
Others
Publication year
2018
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Infection and Drug Resistance
ISSN
1178-6973
e-ISSN
—
Volume of the periodical
11
Issue of the periodical within the volume
12 October
Country of publishing house
NZ - NEW ZEALAND
Number of pages
11
Pages from-to
1807-1817
UT code for WoS article
000447336600001
EID of the result in the Scopus database
2-s2.0-85057602039